APO Research
Talk to an analyst

APO RESEARCH · REPORT

Plasma-derived Factor VIII

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Plasma-derived Factor VIII Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchPlasma-derived Factor VIII Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Plasma-derived Factor VIII Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Plasma-derived Factor VIII Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Plasma-derived Factor VIII Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Plasma-derived Factor VIII Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Plasma-derived Factor VIII market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Plasma-derived Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Plasma-derived Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Plasma-derived Factor VIII is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Plasma-derived Factor VIII market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Plasma-derived Factor VIII market include Takeda, RAAS, Hualan Bio, Octapharma, Kedrion, Grifols, Greencross, CSL and BPL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Plasma-derived Factor VIII market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Plasma-derived Factor VIII and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Plasma-derived Factor VIII sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Plasma-derived Factor VIII market size, projected growth trends, production technologies, key applications, and end-use industries.

Plasma-derived Factor VIII Segment by Company

Takeda

RAAS

Hualan Bio

Octapharma

Kedrion

Grifols

Greencross

CSL

BPL

Plasma-derived Factor VIII Segment by Type

200IU

250IU

Plasma-derived Factor VIII Segment by Application

Hospital

Pharmacy

Plasma-derived Factor VIII Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Plasma-derived Factor VIII status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Plasma-derived Factor VIII market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Plasma-derived Factor VIII significant trends, drivers, influence factors in global and regions.

6. To analyze Plasma-derived Factor VIII competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma-derived Factor VIII market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Plasma-derived Factor VIII and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma-derived Factor VIII.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Plasma-derived Factor VIII market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plasma-derived Factor VIII industry.

Chapter 3: Detailed analysis of Plasma-derived Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Plasma-derived Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Plasma-derived Factor VIII in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Plasma-derived Factor VIII Industry Trends Table 2. Plasma-derived Factor VIII Industry Drivers Table 3. Plasma-derived Factor VIII Industry Opportunities and Challenges Table 4. Plasma-derived Factor VIII Industry Restraints Table 5. Global Plasma-derived Factor VIII Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Plasma-derived Factor VIII Revenue Share by Company (2021-2026) Table 7. Global Plasma-derived Factor VIII Sales Volume by Company (units) & (2021-2026) Table 8. Global Plasma-derived Factor VIII Sales Volume Share by Company (2021-2026) Table 9. Global Plasma-derived Factor VIII Average Price (US$/unit) of Company (2021-2026) Table 10. Global Plasma-derived Factor VIII Company Ranking, (2024-2026) & (USD Million) Table 11. Global Plasma-derived Factor VIII Key Company Manufacturing Base & Headquarters Table 12. Global Plasma-derived Factor VIII Company, Product Type & Application Table 13. Global Plasma-derived Factor VIII Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Plasma-derived Factor VIII by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 200IU Table 18. Significant Companies of 250IU Table 19. Global Plasma-derived Factor VIII Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 20. Global Plasma-derived Factor VIII Sales Volume by Type (2021-2026) & (units) Table 21. Global Plasma-derived Factor VIII Sales Volume by Type (2027-2032) & (units) Table 22. Global Plasma-derived Factor VIII Sales Volume Share by Type (2021-2026) Table 23. Global Plasma-derived Factor VIII Sales Volume Share by Type (2027-2032) Table 24. Global Plasma-derived Factor VIII Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Plasma-derived Factor VIII Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Plasma-derived Factor VIII Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Plasma-derived Factor VIII Sales Value Share by Type (2021-2026) Table 28. Global Plasma-derived Factor VIII Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Global Plasma-derived Factor VIII Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 32. Global Plasma-derived Factor VIII Sales Volume by Application (2021-2026) & (units) Table 33. Global Plasma-derived Factor VIII Sales Volume by Application (2027-2032) & (units) Table 34. Global Plasma-derived Factor VIII Sales Volume Share by Application (2021-2026) Table 35. Global Plasma-derived Factor VIII Sales Volume Share by Application (2027-2032) Table 36. Global Plasma-derived Factor VIII Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Plasma-derived Factor VIII Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Plasma-derived Factor VIII Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Plasma-derived Factor VIII Sales Value Share by Application (2021-2026) Table 40. Global Plasma-derived Factor VIII Sales Value Share by Application (2027-2032) Table 41. Global Plasma-derived Factor VIII Sales by Region: 2021 VS 2025 VS 2032 (units) Table 42. Global Plasma-derived Factor VIII Sales by Region (2021-2026) & (units) Table 43. Global Plasma-derived Factor VIII Sales Market Share by Region (2021-2026) Table 44. Global Plasma-derived Factor VIII Sales by Region (2027-2032) & (units) Table 45. Global Plasma-derived Factor VIII Sales Market Share by Region (2027-2032) Table 46. Global Plasma-derived Factor VIII Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Plasma-derived Factor VIII Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Plasma-derived Factor VIII Sales Value Share by Region (2021-2026) Table 49. Global Plasma-derived Factor VIII Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Plasma-derived Factor VIII Sales Value Share by Region (2027-2032) Table 51. Global Plasma-derived Factor VIII Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Plasma-derived Factor VIII Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Plasma-derived Factor VIII Sales by Country: 2021 VS 2025 VS 2032 (units) Table 54. Global Plasma-derived Factor VIII Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Plasma-derived Factor VIII Sales by Country (2021-2026) & (units) Table 56. Global Plasma-derived Factor VIII Sales Market Share by Country (2021-2026) Table 57. Global Plasma-derived Factor VIII Sales by Country (2027-2032) & (units) Table 58. Global Plasma-derived Factor VIII Sales Market Share by Country (2027-2032) Table 59. Global Plasma-derived Factor VIII Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Plasma-derived Factor VIII Sales Value Market Share by Country (2021-2026) Table 61. Global Plasma-derived Factor VIII Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Plasma-derived Factor VIII Sales Value Market Share by Country (2027-2032) Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Takeda Plasma-derived Factor VIII Product Portfolio Table 67. Takeda Recent Development Table 68. RAAS Company Information Table 69. RAAS Business Overview Table 70. RAAS Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. RAAS Plasma-derived Factor VIII Product Portfolio Table 72. RAAS Recent Development Table 73. Hualan Bio Company Information Table 74. Hualan Bio Business Overview Table 75. Hualan Bio Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Hualan Bio Plasma-derived Factor VIII Product Portfolio Table 77. Hualan Bio Recent Development Table 78. Octapharma Company Information Table 79. Octapharma Business Overview Table 80. Octapharma Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Octapharma Plasma-derived Factor VIII Product Portfolio Table 82. Octapharma Recent Development Table 83. Kedrion Company Information Table 84. Kedrion Business Overview Table 85. Kedrion Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Kedrion Plasma-derived Factor VIII Product Portfolio Table 87. Kedrion Recent Development Table 88. Grifols Company Information Table 89. Grifols Business Overview Table 90. Grifols Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Grifols Plasma-derived Factor VIII Product Portfolio Table 92. Grifols Recent Development Table 93. Greencross Company Information Table 94. Greencross Business Overview Table 95. Greencross Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Greencross Plasma-derived Factor VIII Product Portfolio Table 97. Greencross Recent Development Table 98. CSL Company Information Table 99. CSL Business Overview Table 100. CSL Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. CSL Plasma-derived Factor VIII Product Portfolio Table 102. CSL Recent Development Table 103. BPL Company Information Table 104. BPL Business Overview Table 105. BPL Plasma-derived Factor VIII Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. BPL Plasma-derived Factor VIII Product Portfolio Table 107. BPL Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Plasma-derived Factor VIII Distributors List Table 111. Plasma-derived Factor VIII Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Plasma-derived Factor VIII Product Image Figure 2. Global Plasma-derived Factor VIII Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Plasma-derived Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 4. Global Plasma-derived Factor VIII Sales (2021-2032) & (units) Figure 5. Global Plasma-derived Factor VIII Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Plasma-derived Factor VIII Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 200IU Image Figure 10. 250IU Image Figure 11. Global Plasma-derived Factor VIII Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 12. Global Plasma-derived Factor VIII Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Plasma-derived Factor VIII Sales Volume Share by Type (2021-2032) Figure 14. Global Plasma-derived Factor VIII Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Plasma-derived Factor VIII Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Plasma-derived Factor VIII Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Global Plasma-derived Factor VIII Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 20. Global Plasma-derived Factor VIII Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Plasma-derived Factor VIII Sales Volume Share by Application (2021-2032) Figure 22. Global Plasma-derived Factor VIII Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Plasma-derived Factor VIII Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Plasma-derived Factor VIII Sales Value Share by Application (2021-2032) Figure 25. Global Plasma-derived Factor VIII Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 26. Global Plasma-derived Factor VIII Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Plasma-derived Factor VIII Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Plasma-derived Factor VIII Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Plasma-derived Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 30. North America Plasma-derived Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Plasma-derived Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Plasma-derived Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Plasma-derived Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Plasma-derived Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Plasma-derived Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 36. South America Plasma-derived Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Plasma-derived Factor VIII Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Plasma-derived Factor VIII Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Plasma-derived Factor VIII Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Plasma-derived Factor VIII Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 200IU
  • 250IU
Applications
  • Hospital
  • Pharmacy
Companies covered
  • Takeda
  • RAAS
  • Hualan Bio
  • Octapharma
  • Kedrion
  • Grifols
  • Greencross
  • CSL
  • BPL

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Plasma-derived Factor VIII Sales Value (2021-2032)
  4. 1.2.2 Global Plasma-derived Factor VIII Sales Volume (2021-2032)
  5. 1.2.3 Global Plasma-derived Factor VIII Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Plasma-derived Factor VIII Market Dynamics
  1. 2.1 Plasma-derived Factor VIII Industry Trends
  2. 2.2 Plasma-derived Factor VIII Industry Drivers
  3. 2.3 Plasma-derived Factor VIII Industry Opportunities and Challenges
  4. 2.4 Plasma-derived Factor VIII Industry Restraints
3 Plasma-derived Factor VIII Market by Company
  1. 3.1 Global Plasma-derived Factor VIII Company Revenue Ranking in 2025
  2. 3.2 Global Plasma-derived Factor VIII Revenue by Company (2021-2026)
  3. 3.3 Global Plasma-derived Factor VIII Sales Volume by Company (2021-2026)
  4. 3.4 Global Plasma-derived Factor VIII Average Price by Company (2021-2026)
  5. 3.5 Global Plasma-derived Factor VIII Company Ranking (2024-2026)
  6. 3.6 Global Plasma-derived Factor VIII Company Manufacturing Base and Headquarters
  7. 3.7 Global Plasma-derived Factor VIII Company Product Type and Application
  8. 3.8 Global Plasma-derived Factor VIII Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Plasma-derived Factor VIII Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Plasma-derived Factor VIII Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Plasma-derived Factor VIII Market by Type
  1. 4.1 Plasma-derived Factor VIII Type Introduction
  2. 4.1.1 200IU
  3. 4.1.2 250IU
  4. 4.2 Global Plasma-derived Factor VIII Sales Volume by Type
  5. 4.2.1 Global Plasma-derived Factor VIII Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Plasma-derived Factor VIII Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Plasma-derived Factor VIII Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Plasma-derived Factor VIII Sales Value by Type
  9. 4.3.1 Global Plasma-derived Factor VIII Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Plasma-derived Factor VIII Sales Value by Type (2021-2032)
  11. 4.3.3 Global Plasma-derived Factor VIII Sales Value Share by Type (2021-2032)
5 Plasma-derived Factor VIII Market by Application
  1. 5.1 Plasma-derived Factor VIII Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Plasma-derived Factor VIII Sales Volume by Application
  5. 5.2.1 Global Plasma-derived Factor VIII Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Plasma-derived Factor VIII Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Plasma-derived Factor VIII Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Plasma-derived Factor VIII Sales Value by Application
  9. 5.3.1 Global Plasma-derived Factor VIII Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Plasma-derived Factor VIII Sales Value by Application (2021-2032)
  11. 5.3.3 Global Plasma-derived Factor VIII Sales Value Share by Application (2021-2032)
6 Plasma-derived Factor VIII Regional Sales and Value Analysis
  1. 6.1 Global Plasma-derived Factor VIII Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Plasma-derived Factor VIII Sales by Region (2021-2032)
  3. 6.2.1 Global Plasma-derived Factor VIII Sales by Region: 2021-2026
  4. 6.2.2 Global Plasma-derived Factor VIII Sales by Region (2027-2032)
  5. 6.3 Global Plasma-derived Factor VIII Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Plasma-derived Factor VIII Sales Value by Region (2021-2032)
  7. 6.4.1 Global Plasma-derived Factor VIII Sales Value by Region: 2021-2026
  8. 6.4.2 Global Plasma-derived Factor VIII Sales Value by Region (2027-2032)
  9. 6.5 Global Plasma-derived Factor VIII Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Plasma-derived Factor VIII Sales Value (2021-2032)
  12. 6.6.2 North America Plasma-derived Factor VIII Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Plasma-derived Factor VIII Sales Value (2021-2032)
  15. 6.7.2 Europe Plasma-derived Factor VIII Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Plasma-derived Factor VIII Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Plasma-derived Factor VIII Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Plasma-derived Factor VIII Sales Value (2021-2032)
  21. 6.9.2 South America Plasma-derived Factor VIII Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Plasma-derived Factor VIII Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Plasma-derived Factor VIII Sales Value Share by Country, 2025 VS 2032
7 Plasma-derived Factor VIII Country-level Sales and Value Analysis
  1. 7.1 Global Plasma-derived Factor VIII Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Plasma-derived Factor VIII Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Plasma-derived Factor VIII Sales by Country (2021-2032)
  4. 7.3.1 Global Plasma-derived Factor VIII Sales by Country (2021-2026)
  5. 7.3.2 Global Plasma-derived Factor VIII Sales by Country (2027-2032)
  6. 7.4 Global Plasma-derived Factor VIII Sales Value by Country (2021-2032)
  7. 7.4.1 Global Plasma-derived Factor VIII Sales Value by Country (2021-2026)
  8. 7.4.2 Global Plasma-derived Factor VIII Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Plasma-derived Factor VIII Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Plasma-derived Factor VIII Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Plasma-derived Factor VIII Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Plasma-derived Factor VIII Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 RAAS
  8. 8.2.1 RAAS Company Information
  9. 8.2.2 RAAS Business Overview
  10. 8.2.3 RAAS Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 RAAS Plasma-derived Factor VIII Product Portfolio
  12. 8.2.5 RAAS Recent Developments
  13. 8.3 Hualan Bio
  14. 8.3.1 Hualan Bio Company Information
  15. 8.3.2 Hualan Bio Business Overview
  16. 8.3.3 Hualan Bio Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Hualan Bio Plasma-derived Factor VIII Product Portfolio
  18. 8.3.5 Hualan Bio Recent Developments
  19. 8.4 Octapharma
  20. 8.4.1 Octapharma Company Information
  21. 8.4.2 Octapharma Business Overview
  22. 8.4.3 Octapharma Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Octapharma Plasma-derived Factor VIII Product Portfolio
  24. 8.4.5 Octapharma Recent Developments
  25. 8.5 Kedrion
  26. 8.5.1 Kedrion Company Information
  27. 8.5.2 Kedrion Business Overview
  28. 8.5.3 Kedrion Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kedrion Plasma-derived Factor VIII Product Portfolio
  30. 8.5.5 Kedrion Recent Developments
  31. 8.6 Grifols
  32. 8.6.1 Grifols Company Information
  33. 8.6.2 Grifols Business Overview
  34. 8.6.3 Grifols Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Grifols Plasma-derived Factor VIII Product Portfolio
  36. 8.6.5 Grifols Recent Developments
  37. 8.7 Greencross
  38. 8.7.1 Greencross Company Information
  39. 8.7.2 Greencross Business Overview
  40. 8.7.3 Greencross Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Greencross Plasma-derived Factor VIII Product Portfolio
  42. 8.7.5 Greencross Recent Developments
  43. 8.8 CSL
  44. 8.8.1 CSL Company Information
  45. 8.8.2 CSL Business Overview
  46. 8.8.3 CSL Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CSL Plasma-derived Factor VIII Product Portfolio
  48. 8.8.5 CSL Recent Developments
  49. 8.9 BPL
  50. 8.9.1 BPL Company Information
  51. 8.9.2 BPL Business Overview
  52. 8.9.3 BPL Plasma-derived Factor VIII Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 BPL Plasma-derived Factor VIII Product Portfolio
  54. 8.9.5 BPL Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Plasma-derived Factor VIII Value Chain Analysis
  2. 9.1.1 Plasma-derived Factor VIII Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Plasma-derived Factor VIII Sales Mode & Process
  6. 9.2 Plasma-derived Factor VIII Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Plasma-derived Factor VIII Distributors
  9. 9.2.3 Plasma-derived Factor VIII Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst